Combination of maintenance hemodialysis with hemoperfusion: A safe and effective model of artificial kidney

International Journal of Artificial Organs

Volumn 34, Issue 4, 2011, Pages 339-347

  Chen, Shun Jie ^a   Jiang, Geng Ru ^a   Shan, Jian Ping ^a   Lu, Wei ^a   Huang, Hai Dong ^a   Ji, Gang ^a   Wu, Ping ^a   Wu, Gu Feng ^a   Wang, Wei ^a   Zhu, Chun ^a   Bian, Fan ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Artificial kidney; Hemoperfusion; Maintenance hemodialysis; Middle and large molecule uremic toxins

Indexed keywords

ARTIFICIAL ORGANS; BLOOD PRESSURE; BODY FLUIDS; DRUG DOSAGE; GLYCOPROTEINS; HEMODIALYZERS; IRON; MAINTENANCE; METABOLITES; MOLECULES; PATIENT MONITORING; RATS; SURVEYS;

ARTIFICIAL KIDNEY; C-REACTIVE PROTEINS; HAEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOPERFUSION; LEPTINS; MAINTENANCE HEMODIALYSIS; MIDDLE AND LARGE MOLECULE UREMIC TOXIN; QUALITY OF LIFE; UREMIC TOXINS;

DIALYSIS;

ANTIHYPERTENSIVE AGENT; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; INTERLEUKIN 6; LEPTIN; PARATHYROID HORMONE; SERUM ALBUMIN; TUMOR NECROSIS FACTOR ALPHA; UREMIC TOXIN;

ADULT; ARTICLE; ARTIFICIAL KIDNEY; BODY MASS; DEATH; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART OUTPUT; HEART RATE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HEMOPERFUSION; HUMAN; IRON BINDING CAPACITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

EID: 79955664965     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.5301/IJAO.2011.7748     Document Type: Article

References (18)

1. Bammens B, Evenepoel P, Verbeke K, et al. Removal of the protein-bound solute p-cresol by convective transport: a randomized crossorer study. Am J Kidney Dis. 2004;44(2):278-285. Medline. doi:10.1053/j.ajkd.2004.04.033
2. Mandolfo S, Borlandelli S, Imbasciati E. Leptin and beta 2-microglobulin kinetics with three different dialysis modalities. Int J Artif Organs. 2006;29(10):949-955 Medline.
3. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 1993;4(5):1205-1213 Medline.
4. Stenvinkel P, Pecoits-Filho R, Lindholm B. Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease? Adv Ren Replace Ther. 2003;10(4):332-345 Medline. doi:10.1053/j.arrt.2003.08.009
5. Menaa C, Esser E, Sprague SM. Beta2-microglobulin stimulates osteoclast formation. Kidney Int. 2008;73(11):1275-1281 Medline. doi:10.1038/ki.2008.100
6. London G M, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15(7):1943-1951. Medline. doi:10.1097/01. ASN.0000129337.50739.48
7. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. J Crohn's Colitis. 2010;4(4):355-366. doi:10.1016/j.crohns.2010.04.004
8. Pizzarelli F, Cerrai T, Dattolo P, Tetta C, Maggiore Q. Convective treatments with on-line production of replacement fluid: a clinical experience lasting 6 years. Nephrol Dial Transplant. 1998;13(2):363-369. Medline. doi:10.1093/ndt/13.2.361
9. Canaud B, Bosc JY, Leray H, et al. On-line haemodiafiltration: state of the art. Nephrol Dial Transplant. 1998;13(Suppl 5):3-11. Medline. doi:10.1093/ndt/13.suppl_5.3
10. Winchester JF. Sorbent hemoperfusion in end-stage renal disease: an in-depth review. Adv Ren Replace Ther. 2002;9(1):19-25. Medline. doi:10.1053/jarr.2002.30472
11. Winchester JF, Ronco C, Brady JA, et al. The next step from high-flux dialysis: application of sorbent technology. Blood Purif. 2002;20(1):81-86. Medline. doi:10.1159/000046989
12. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63(5):1934-1943. Medline. doi:10.1046/j.1523-1755.2003.00924.x
13. Vanholder RC, Glorieux GL. An overview of uremic toxicity. Hemodial Int. 2003;7(2):156-161. Medline. doi:10.1046/j.1492-7535.2003.00034.x
14. Xu X, Yang Y, Zhu N. Characteristics and molecular mechanism of adhesion proteins on reused hemodialysis membranes. Blood Purif. 2009;27(4):321-329. Medline. doi:10.1159/000207199
15. Wang JY, Hotta T, Murate T, et al. Growth inhibition of erythroid colonies by antolongous sera and the clinical effect of erythropoirtin in chronic renal disease. Rinsho Ketsueki. 1989;30(7):975-979. Medline.
16. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem. 2002;48(7):1066-1076. Medline.
17. Hackeng CM, Beerenhout CM, Hermans M, et al. The relationship between reticulocyte hemoglobin content with Creactive protein and conventional iron parameters in dialysis patients. J Nephrol. 2004;17(1):107-111. Medline.
18. Morena MD, Guo D, Balakrishnan VS., et al. Effect of a novel adsorbent on cytokine responsiveness to uremic plasma. Kidney Int. 2003;63(3):1150-1154. doi:10.1046/j.1523-1755.2003.00839.x